

(FILE 'HOME' ENTERED AT 17:05:41 ON 02 JUN 1998)

FILE 'MEDLINE, EMBASE, WPIDS, CAPLUS' ENTERED AT 17:08:13 ON 02 JUN 1998

L1 38025 S TIE OR TIE1 OR TIE2 OR HTIE?
L2 49 S L1(10A)LIGAND?
L3 27 DUP REM L2 (22 DUPLICATES REMOVED)
L4 127 S NL1
L5 19 S L4(15A) (PROTEIN OR POLYPEPTIDE OR CDNA OR MRNA OR CLON
L6 0 S L4(15A) (HEART OR MUSCLE OR PANCREASE OR CARTILAG? OR P
L7 8 DUP REM L5 (11 DUPLICATES REMOVED)
E GODOWSKI P/IN
L8 16 S E4 OR E5
E GODOWSKI P/AU
L9 135 S E4-E8
E GURNEY A/AU
L10 48 S E4 OR E10 OR E11 OR E9
L11 182 S L8 OR L9 OR L10
L12 47 S L11 AND (TIE OR LIGAND? OR ANGIO? OR TIE1 OR TIE2)
L13 21 DUP REM L12 (26 DUPLICATES REMOVED)

14.12.17/26
014

L3 ANSWER 1 OF 27 WPIDS COPYRIGHT 1998 DERWENT INFORMATION LTD
 DUPLICATE 1
 AN 98-145615 [13] WPIDS
 CR 98-063143 [06]
 DNN N98-115160 DNC C98-047680
 TI Modified human **TIE**-2 receptor **ligand(s)** - useful
 for promoting wound healing.
 DC B04 D16 S03
 IN DAVIS, S; YANCOPOULOS, G D
 PA (REGE-N) REGENERON PHARM INC
 CYC 77
 PI WO 9805779 A1 980212 (9813)* EN 202 pp C12N015-12
 RW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL
 OA PT SD SE SZ UG ZW
 W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI
 GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD
 MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
 TT UA UG UZ VN YU ZW
 ADT WO 9805779 A1 WO 97-US13557 970801
 PRAI US 96-740223 961025; US 96-22999 960802
 IC ICM C12N015-12
 ICS A61K038-17; A61K038-18; A61K039-395; A61K049-00; A61K051-08;
 C07K014-515; C07K014-71; C07K016-22; C07K019-00; C12N015-62;
 C12Q001-48; C12Q001-68; G01N033-53; G01N033-68

L3 ANSWER 7 OF 27 WPIDS COPYRIGHT 1998 DERWENT INFORMATION LTD
 DUPLICATE 4
 AN 98-063143 [06] WPIDS
 CR 98-145615 [13]
 DNC C98-022151
 TI DNA encoding **TIE ligands** 3 and 4 - useful for,
 e.g. blocking blood vessel growth and promoting neovascularisation,
 etc..
 DC B04 D16
 IN JONES, P F; VALENZUELA, D M; YANCOPOULOS, G D
 PA (REGE-N) REGENERON PHARM INC
 CYC 76
 PI WO 9748804 A2 971224 (9806)* EN 86 pp C12N015-12
 RW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL
 OA PT SD SE SZ UG ZW
 W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI
 GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG
 MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA
 UG US UZ VN
 AU 9734061 A 980107 (9820) C12N015-12
 ADT WO 9748804 A2 WO 97-US10728 970619; AU 9734061 A AU 97-34061 970619
 FDT AU 9734061 A Based on WO 9748804
 PRAI US 96-22999 960802; US 96-665926 960619; US 96-21087 960702
 IC ICM C12N015-12
 ICS A61K038-18; C07K014-17; C07K014-745; C07K016-22

L3 ANSWER 13 OF 27 WPIDS COPYRIGHT 1998 DERWENT INFORMATION LTD
 DUPLICATE 9
 AN 96-209850 [21] WPIDS
 CR 96-465021 [46]
 DNC C96-067047
 TI Nucleic acid encoding **TIE-2 ligand** and related

vectors - useful diagnosis and treatment of neovascularisation, tumours, etc., or to promote wound healing, etc..

DC B04 C06 D16

IN ALDRICH, T H; BRUNO, J; DAVIS, S; GOLDFARB, M; JONES, P F; MAISONPIERRE, P C; RADZIEJEWSKI, C; YANCOPOULOS, G D; YANCOUPOULOS, G D; ALDRICH, T

PA (REGE-N) REGENERON PHARM INC

CYC 68

PI WO 9611269 A2 960418 (9621)* EN 84 pp C12N015-12
 RW: AT BE CH DE DK ES FR GB GR IE IT KE LU MC MW NL OA PT SD SE SZ UG
 W: AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN
 US 5521073 A 960528 (9627) 15 pp C12N015-12
 AU 9641295 A 960502 (9632) C12N015-12
 ZA 9508444 A 970625 (9731) 77 pp C12N000-00
 US 5643755 A 970701 (9732) 13 pp C12N015-12
 EP 784683 A1 970723 (9734) EN C12N015-12
 R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
 NO 9701557 A 970606 (9734) C07K014-47
 US 5650490 A 970722 (9735) 32 pp A61K038-18
 FI 9701406 A 970604 (9736) C12N000-00
 CZ 9701025 A3 970917 (9743) C12N015-12

ADT WO 9611269 A2 WO 95-US12935 951006; US 5521073 A CIP of US 94-319932 941007, US 94-330261 941027; AU 9641295 A AU 96-41295 951006; ZA 9508444 A ZA 95-8444 951006; US 5643755 A US 94-319932 941007; EP 784683 A1 EP 95-939501 951006, WO 95-US12935 951006; NO 9701557 A WO 95-US12935 951006, NO 97-1557 970404; US 5650490 A CIP of US 94-319932 941007, CIP of US 94-330261 941027, CIP of US 94-348492 941202, CIP of US 94-353503 941209, US 95-373579 950117; FI 9701406 A WO 95-US12935 951006, FI 97-1406 970404; CZ 9701025 A3 WO 95-US12935 951006, CZ 97-1025 951006

FDT AU 9641295 A Based on WO 9611269; EP 784683 A1 Based on WO 9611269; US 5650490 A CIP of US 5521073; CZ 9701025 A3 Based on WO 9611269

PRAI US 95-418595 950406; US 94-319932 941007; US 94-330261 941027; US 94-348492 941202; US 94-353503 941209; US 95-373579 950117

IC ICM A61K038-18; C07K014-47; C12N000-00; C12N015-12
 ICS A61K038-17; A61K039-395; A61K047-48; A61K051-00; C07K013-00; C07K014-475; C07K014-705; C07K014-71; C07K016-22; C07K016-28; C12N005-06; C12N015-62; G01N000-00

L3 ANSWER 14 OF 27 WPIDS COPYRIGHT 1998 DERWENT INFORMATION LTD

AN 96-465021 [46] WPIDS

CR 96-209850 [21]

DNC C96-146085

TI TIE-2 agonists and antagonists and related DNA - useful for promoting or blocking neovascularisation, etc.

DC B04 C06 D16

IN ALDRICH, T H; BRUNO, J; DAVIS, S; GOLDFARB, M; JONES, P F; MAISONPIERRE, P C; RADZIEJEWSKI, C; YANCOPOULOS, G D

PA (REGE-N) REGENERON PHARM INC

CYC 22

PI WO 9631598 A1 961010 (9646)* EN 113 pp C12N015-00
 RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
 W: AU CA JP US
 AU 9653871 A 961023 (9707) C12N015-00
 EP 821728 A1 980204 (9810) EN C12N015-00
 R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

ADT WO 9631598 A1 WO 96-US4806 960405; AU 9653871 A AU 96-53871 960405; EP 821728 A1 EP 96-910769 960405, WO 96-US4806 960405

FDT AU 9653871 A Based on WO 9631598; EP 821728 A1 Based on WO 9631598

PRAI WO 95-US12935 951006; US 95-418595 950406

IC ICM C12N015-00

ICS A61K038-19; C07K014-52; C07K019-00; C12N001-20

L3 ANSWER 21 OF 27 WPIDS COPYRIGHT 1998 DERWENT INFORMATION LTD
 AN 95-194105 [25] WPIDS
 DNC C95-089857
 TI New tie-2 receptor tyrosine kinase and related nucleic acid - and methods for detecting tie-2 modulators for treating eg cancer, associated with angiogenesis and vasculogenesis.
 DC B04 D16
 IN RISAU, W
 PA (PLAC) MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN
 CYC 58
 PI WO 9513387 A1 950518 (9525)* EN 81 pp C12N015-63
 RW: AT BE CH DE DK ES FR GB GR IE IT KE LU MC MW NL OA PT SD SE SZ
 W: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN
 AU 9481430 A 950529 (9537) C12N015-63
 ADT WO 9513387 A1 WO 94-EP3767 941112; AU 9481430 A AU 94-81430 941112
 FDT AU 9481430 A Based on WO 9513387
 PRAI US 93-152552 931112
 IC ICM C12N015-63
 ICS C07K014-47; C07K014-515; C07K016-28; C12N005-16; C12N015-62

L3 ANSWER 24 OF 27 WPIDS COPYRIGHT 1998 DERWENT INFORMATION LTD
 AN 93-243152 [30] WPIDS
 DNC C93-108374
 TI Nucleic acid encoding tyrosine kinase receptor - for regulating tie activity in diagnosis and treatment of neoplastic diseases involving tumour angiogenesis, wound healing etc..
 DC B04 D16
 IN ALITALO, K; ARMSTRONG, E; KORHONEN, J; MAEKELA, T P; PARTANEN, J; MAEKELAE, T P; MAKELAE, T P
 PA (UYHE-N) UNIV HELSINKI HOLDING LTD
 CYC 42
 PI WO 9314124 A1 930722 (9330)* EN 73 pp C07K013-00
 RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL OA PT SE
 W: AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US
 AU 9333532 A 930803 (9348) C07K013-00
 FI 9403275 A 940711 (9435) C07K000-00
 EP 620826 A1 941026 (9441) EN C07K013-00
 R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
 JP 07506242 W 950713 (9536) 21 pp C12N015-09
 HU 69792 T 950928 (9546) C07K014-00
 ADT WO 9314124 A1 WO 93-FI6 930108; AU 9333532 A AU 93-33532 930108, WO 93-FI6 930108; FI 9403275 A WO 93-FI6 930108, FI 94-3275 940708; EP 620826 A1 EP 93-902261 930108, WO 93-FI6 930108; JP 07506242 W JP 93-512170 930108, WO 93-FI6 930108; HU 69792 T WO 93-FI6 930108, HU 94-2057 930108
 FDT AU 9333532 A Based on WO 9314124; EP 620826 A1 Based on WO 9314124; JP 07506242 W Based on WO 9314124; HU 69792 T Based on WO 9314124
 PRAI US 92-817800 920109
 IC ICM C07K013-00; C07K014-00; C12N015-09
 ICS C07H021-04; C12N005-10; C12N009-12; C12N015-54

L3 ANSWER 19 OF 27 MEDLINE DUPLICATE 13
 TI Predominant expression of a receptor tyrosine kinase, TIE, in
 hematopoietic stem cells and B cells.
 AU Hashiyama M; Iwama A; Ohshiro K; Kurozumi K; Yasunaga K; Shimizu Y;
 Masuho Y; Matsuda I; Yamaguchi N; Suda T
 SO BLOOD, (1996 Jan 1) 87 (1) 93-101.
 Journal code: A8G. ISSN: 0006-4971.

L3 ANSWER 18 OF 27 MEDLINE DUPLICATE 12
 TI Isolation of angiopoietin-1, a **ligand** for the **TIE2**
 receptor, by secretion-trap expression cloning [see comments].
 AU Davis S; Aldrich T H; Jones P F; Acheson A; Compton D L; Jain V;
 Ryan T E; Bruno J; Radziejewski C; Maisonpierre P C; Yancopoulos G D
 SO CELL, (1996 Dec 27) 87 (7) 1161-9.
 Journal code: CQ4. ISSN: 0092-8674.

L3 ANSWER 15 OF 27 CAPLUS COPYRIGHT 1998 ACS
 TI Cloning and expression of human **TIE-2 ligand**
 cDNA
 IN Davis, Samuel; Aldrich, Thomas H.; Yancopoulos, George D.
 SO U.S., 15 pp. Cont.-in-part of U.S. Ser. No. 319,932.
 CODEN: USXXAM

L3 ANSWER 11 OF 27 MEDLINE DUPLICATE 7
 TI [Angiopoietin-2, a new molecular actor involved in vascular tree
 morphogenesis].
 L'angiopoietine 2, un nouvel acteur moleculaire implique dans la
 morphogen`ese de l'arbre vasculaire.
 AU Vandenbunder B
 SO BULLETIN DU CANCER, (1997 Nov) 84 (11) 1079-80.
 Journal code: BDZ. ISSN: 0007-4551.

L3 ANSWER 8 OF 27 CAPLUS COPYRIGHT 1998 ACS
 TI Receptor tyrosine kinase **TIE-2 ligand** and
 pharmaceutical compositions containing **TIE-2**
ligand or **TIE-2 ligand** conjugates
 IN Davis, Samuel; Jones, Pamela F.; Yancopoulos, George D.
 SO U.S., 32 pp. Cont.-in-part of U.S. Ser. No. 353,503.
 CODEN: USXXAM

L3 ANSWER 6 OF 27 EMBASE COPYRIGHT 1998 ELSEVIER SCI. B.V. DUPLICATE 3
 TI Endothelial **Tie2/Tek ligands** angiopoietin-1
 (ANGPT1) and angiopoietin-2 (ANGPT2): Regional localization of the
 human genes to 8q22.3-q23 and 8p23.
 AU Cheung A.H.; Stewart R.J.; Marsden P.A.
 SO Genomics, (15 Mar 1998) 48/3 (389-391).
 Refs: 5
 ISSN: 0888-7543 CODEN: GNMCEP

L3 ANSWER 4 OF 27 EMBASE COPYRIGHT 1998 ELSEVIER SCI. B.V.
 TI Renal microvascular assembly and repair: Power and promise of
 molecular definition.
 AU Takahashi T.; Huynh-Do U.; Daniel T.O.
 SO Kidney International, (1998) 53/4 (826-835).
 Refs: 93
 ISSN: 0085-2538 CODEN: KDYIA5

=> d ab 4

AB Developmental assembly of the renal microcirculation is a precise and coordinated process now accessible to experimental scrutiny. Although definition of the cellular and molecular determinants is incomplete, recent findings have reframed concepts and questions about the origins of vascular cells in the glomerulus and the molecules that direct cell recruitment, specialization and morphogenesis. New findings illustrate principles that may be applied to defining critical steps in microvascular repair following glomerular injury. Developmental assembly of endothelial, mesangial and epithelial cells into glomerular capillaries requires that a coordinated, temporally defined series of steps occur in an anatomically ordered sequence. Recent evidence shows that both vasculogenic and angiogenic processes participate. Local signals direct cell migration, proliferation, differentiation, cell-cell recognition, formation of intercellular connections, and morphogenesis. Growth factor receptor tyrosine kinases on vascular cells are important mediators of many of these events. Cultured cell systems have suggested that basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and vascular endothelial growth factor (VEGF) promote endothelial cell proliferation, migration or morphogenesis, while genetic deletion experiments have defined an important role for PDGF .beta. receptors and platelet-derived growth factor (PDGF) B in glomerular development. Receptor tyrosine kinases that convey non-proliferative signals also contribute in kidney and other sites. The EphB1 receptor, one of a diverse class of Eph receptors implicated in neural cell targeting, directs renal endothelial migration, cell-cell recognition and assembly, and is expressed with its **ligand** in developing glomeruli. Endothelial **TIE2** receptors bind angiopoietins (1 and 2), the products of adjacent supportive cells, to signals direct capillary maturation in a sequence that defines cooperative roles for cells of different lineages. Ultimately, definition of the cellular steps and molecular sequence that direct microvascular cell assembly promises to identify therapeutic targets for repair and adaptive remodeling of injured glomeruli.